

Modular Polyketide Synthases and *cis* Double Bond Formation: Establishment of Activated *cis*-3-Cyclohexylpropenoic Acid as the Diketide Intermediate in Phoslactomycin Biosynthesis

Mamoun M. Alhamadsheh, Nadaraj Palaniappan, Suparna DasChoudhuri,[‡] and Kevin A. Reynolds*

Department of Chemistry, Portland State University, Portland, Oregon 97207

Received December 15, 2006; E-mail: reynoldsk@pdx.edu

Phoslactomycins (PLMs), exemplified by PLM B (Figure 1), are a unique class of antitumor, antiviral, and antifungal polyketide natural products.^{1,2} The antitumor activity of PLMs is attributed to a potent and selective inhibition of protein Ser/Thr phosphatase 2A (PP2A).³ The PLM biosynthetic gene cluster from *Streptomyces* sp. HK803 has been cloned and sequenced.⁴ The PLM polyketide synthase (PKS) is a modular PKS comprised of a loading domain and seven extension modules which are responsible for the synthesis of a unique linear unsaturated polyketide structure containing three *cis* (*Z*) and one *trans* (*E*) double bonds.

Modular PKSs which generate unsaturated products typically do so using *trans* double bonds.⁵ These double bonds are established by ketoreductase–dehydratase (KR–DH) domains which sequentially carry out ketoreduction and dehydration steps on the 3-ketoacyl-ACP products of the KS domains. The dehydration step makes the stereochemical course of the KR-catalyzed step cryptic. Recently, *in vitro* work using a DH-inactivated module 2 of the pikromycin PKS, which establishes the single *trans* double bond of pikromycin and methymycin, has shown this KR generates the D-3-hydroxy product.⁶ A bioinformatic analysis of other cryptic KR–DH domains which generate *trans* double bonds infers a D-hydroxyl configuration (this analysis is based on an established correlation of diagnostic residues in KR primary sequences and their known stereochemical products).^{5,7}

Polyketide products containing *cis* double bonds are rare and appear to arise through a variety of mechanisms.⁸ In many cases, such as modules 7 of PLM and module 4 of the epothilone PKS, the required DH activity is absent from the module.^{4,9} Modules 1 and 2 of the PLM PKS are intriguing because they have combined KR–DH didomains which appear to establish two conjugated *cis* double bonds (C₁₂–C₁₃ and C₁₄–C₁₅ of PLM B, respectively).⁴ Bioinformatic analysis of the primary sequence of these KR domains does not clearly predict a D-hydroxyl configuration (which evidence indicates precedes *trans* double bond formation) or L-hydroxy configuration (which has been speculated might precede *cis* double bond formation).⁷ Thus, in each case, the combined activity of these KR–DH didomains might establish a *trans* double bond with a subsequent isomerization step to a *cis* double bond (epimerization domains, in both PKS¹⁰ and NRPS¹¹ modules, as well as *trans* to *cis* double bond isomerization in retinoid cycle¹² have been reported). Alternatively, these KR–DH domains might establish the *cis* double bond directly.

In this work, we have distinguished between these two possibilities by determining the stereochemistry of the polyketide intermediate which is transferred from module 1 to module 2. PLM1 contains a loading domain and the first extension module of the PKS and is predicted to generate either *cis*- or *trans*-3-cyclohexylpropenoic acid (Figure 2) from an activated cyclohexanecarboxylic acid (CHC)




Figure 1. Phoslactomycin B (PLM B).

starter unit. We generated a $\Delta chcA$ mutant (NP3), blocked in biosynthesis of the starter unit, and demonstrated that it only produces PLM B when grown in the presence of CHC (Table 1). The *trans*- and *cis*-diketide products of PLM1 were synthesized in both the acid (**2a** and **3a**, Figure 2) and *N*-acetylcysteamine (SNAC) thioester (**4a** and **5a**, Figure 2) forms and added to separate fermentations of this $\Delta chcA$ mutant. Surprisingly, compounds **2a–5a** all restored PLM B production. PLM B production levels were the highest for the *trans* products (**2a** and **4a**) and were 40% higher than that observed with either CHC supplementation or the *cis*-SNAC (**5a**) (Table 1). The lowest level of PLM B production was observed with the *cis*-acid (**3a**). Interestingly, the PLM B isolated from feeding *trans*-acid **2a** had the C₁₄–C₁₅ double bond in the *cis* configuration, as confirmed by ¹H NMR and NOESY experiments. This initial result suggested that the *trans*-diketide intermediate might be the preferred substrate for PLM2, with a subsequent *trans* to *cis* isomerization step.

Alternatively, the *trans* compounds might be converted efficiently to the activated CHC starter unit by fatty acid degradation and subsequently elongated by the entire PLM PKS (in this way, the *trans* double bond would be lost through degradation and reintroduced as a *cis* double bond by PLM1) (Figure 2). To distinguish between these two hypotheses, we synthesized and fed the [2-¹³C]-labeled analogues **2b–5b** (Figure 2) to the $\Delta chcA$ mutant. Mass spectroscopy revealed that isotopic enrichment over natural abundance for the PLM B product was only observed with the *cis*-SNAC **5b** (20% isotope enrichment, Table 2). These data showed that both *cis* and *trans* compounds undergo degradation to form the activated CHC starter unit, and that this is the primary route for PLM B production in these experiments. Furthermore, the experiments established that only *cis*-SNAC (**5a**, **5b**) could prime PLM2 directly. The *cis*-acid (**3a**, **3b**), which gives the lowest levels of PLM B restoration levels, can be transported into the mutant and degraded to the activated CHC (at about 50% the efficiency of the corresponding *trans*-diketides) but cannot be activated intact such that it can prime PLM2.

A consistent and predictable set of results was obtained by generation and analysis of a *plm1* deletion mutant [NP9, see Supporting Information] (Figure 2). PLM B production was abrogated in this mutant and was only significantly restored by growth in the presence of the *cis*-SNAC compounds **5a** and its ¹³C-labeled counterpart **5b** (Table 1). In the case of **5b**, the PLM B now contained the same level of isotopic enrichment (>99%) as

[‡] Current address: Virginia Commonwealth University.




Figure 2. Incorporation of CHC, compounds **2a–5a**, and **2b–5b** into PLM1 and PLM2 of PLM B PKS.

Table 1. Relative % of PLM B Production by Feeding CHC and Compounds **2a–5a** to $\Delta chcA$ and $\Delta plm1$ Mutants

substrate	$\Delta chcA$ mutant	$\Delta plm1$ mutant
control	0	0
CHC	68 ± 3.9	0
2a	100 ± 7	0
3a	50 ± 3	0
4a	98 ± 6	~0.5 ^a
5a	72 ± 7	100

^a LC–MS analysis demonstrated that **4a** contained trace levels of **5a** (<1%).

Table 2. Percent of ¹³C Isotope Enrichment in Produced PLM B Generated by Feeding CHC and Compounds **2b–5b** to $\Delta chcA$ and $\Delta plm1$ Mutants

substrate	$\Delta chcA$ mutant	$\Delta plm1$ mutant
control	0	ND
CHC	0	ND
2b	0	ND
3b	0	ND
4b	0	99% ^a
5b	~20%	99%

^a LC–MS analysis demonstrated that **4b** contained trace levels of **5b** (<1%). ND: No PLM B production was detected.

the diketide substrate (Table 2). No restoration of PLM B was seen with *cis*- or *trans*-acids (**2a**, **2b**, **3a**, **3b**), and low levels of PLM B were observed with the *trans*-SNAC diketides (**4a**, **4b**) and correlated with LC–MS detection of trace levels of the corresponding *cis*-SNAC diketides (**5a**, **5b**) in these samples (Tables 1 and 2).

These observations unequivocally demonstrate that only the SNAC derivative of the *cis*-diketide can prime PLM2 directly and that all other diketides give rise to PLM B production only through

degradation to an activated CHC and elongation using PLM1. The product of PLM1 must therefore be the *cis*-3-cyclohexylpropenoic acid. These experiments also demonstrate that the PLM biosynthetic process cannot process the *trans*-diketide intermediate either into PLM B (ruling out an isomerization domain in the subsequent PKS modules) or a PLM analogue with *trans* C₁₄–C₁₅ double bond. This last observation indicates significant challenges to successful alteration of the stereochemistry of unsaturated polyketide products through either directed biosynthesis or KR–DH didomain switches.

Acknowledgment. Funding for this research was generously provided by the National Institutes of Health (AI51629).

Supporting Information Available: Experimental procedures and spectroscopic data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Fushimi, S.; Nishikawa, S.; Shimazu, A.; Seto, H. *J. Antibiot.* **1989**, *42*, 1019–1025.
- (2) Fushimi, S.; Furihata, K.; Seto, H. *J. Antibiot.* **1989**, *42*, 1026–1036.
- (3) Usui, T.; Marriott, G.; Inagaki, M.; Swarup, G.; Osada, H. *J. Biochem.* **1999**, *125*, 960–965.
- (4) Palaniappan, N.; Kim, B. S.; Sekiyama, Y.; Osada, H.; Reynolds, K. A. *J. Biol. Chem.* **2003**, *278*, 35552–35557.
- (5) Reid, R.; Piagentini, M.; Rodriguez, E.; Ashley, G.; Viswanathan, N.; Carney, J.; Santi, D. V.; Hutchinson, C. R.; McDaniel, R. *Biochemistry* **2003**, *42*, 72–79.
- (6) Wu, J.; Zaleski, T. J.; Valenzano, C.; Khosla, C.; Cane, D. E. *J. Am. Chem. Soc.* **2005**, *127*, 17393–17404.
- (7) Caffrey, P. *ChemBioChem* **2003**, *4*, 654–657.
- (8) August, P. R.; Lang, T.; Yoon, Y. J.; Ning, S.; Muller, R.; Yu, T. W.; Taylor, M.; Hoffman, D.; Kim, C. G.; Zhang, X.; Hutchinson, C. R.; Floss, H. G. *Chem. Biol.* **1998**, *5*, 69–79.
- (9) Tang, L.; Shah, S.; Chung, L.; Carney, J.; Katz, L.; Khosla, C.; Julien, B. *Science* **2000**, *287*, 640–642.
- (10) Holzbaur, I. E.; Ranganathan, A.; Thomas, I. P.; Kearney, D. J.; Reather, J. A.; Rudd, B. A.; Staunton, J.; Leadlay, P. F. *Chem. Biol.* **2001**, *8*, 329–340.
- (11) Patel, H. M.; Tao, J.; Walsh, C. T. *Biochemistry* **2003**, *42*, 10514–10527.
- (12) Golczak, M.; Kuksa, V.; Maeda, T.; Moise, A. R.; Palczewski, K. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 8162–8167.

JA068818T